Akoya Biosciences Inc (AKYA)
4.04
+0.05
(+1.25%)
USD |
NASDAQ |
May 03, 16:00
4.04
0.00 (0.00%)
After-Hours: 20:00
Akoya Biosciences Cash from Operations (TTM): -50.90M for Dec. 31, 2023
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
Date | Value |
---|---|
December 31, 2023 | -50.90M |
September 30, 2023 | -55.32M |
June 30, 2023 | -53.74M |
March 31, 2023 | -55.32M |
December 31, 2022 | -53.50M |
September 30, 2022 | -49.34M |
June 30, 2022 | -50.57M |
Date | Value |
---|---|
March 31, 2022 | -49.60M |
December 31, 2021 | -36.07M |
September 30, 2021 | -32.36M |
June 30, 2021 | -20.71M |
March 31, 2021 | -10.29M |
December 31, 2020 | -6.843M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-55.32M
Minimum
Mar 2023
-6.843M
Maximum
Dec 2020
-40.35M
Average
-49.60M
Median
Mar 2022
Cash from Operations (TTM) Benchmarks
Bruker Corp | 284.40M |
Azenta Inc | 70.94M |
Harvard Bioscience Inc | 14.03M |
Bionano Genomics Inc | -125.18M |
Singular Genomics Systems Inc | -73.65M |